Euroscreen, Medarex sign licensing deal to develop antibody products against two targets

By E. Janene Geiss

Philadelphia, June 26 - Medarex, Inc. and Euroscreen SA announced Monday the completion of a license and research agreement for the exclusive worldwide development and commercialization of antibody-based products against certain targets for various diseases, including inflammatory and autoimmune conditions.

Medarex said it intends to use its UltiMAb technology to create antibodies to targets provided by Euroscreen, according to a company news release.

Under the agreement, Euroscreen said it has granted Medarex exclusive rights to develop and commercialize antibody products against two undisclosed targets.

Euroscreen said it will receive an upfront payment and may receive milestone payments and royalties on any future sales of products developed and commercialized by Medarex.

Medarex and Euroscreen said they reserve the right to collaborate on certain preclinical activities in support of the development of such products.

Financial details were not disclosed.

Euroscreen is a privately held biopharmaceutical company based in Brussels, Belgium.

Medarex is a Princeton, N.J., biopharmaceutical company focused on fully human antibody-based therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.